AstraZeneca says a strong 2024 and stacked pipeline spells potential for further growth in 2025 as the company aims to bring in $80bn in revenue by 2030. The company maintains a confident outlook ...

These results were announced at the 2025 ASCO Annual Meeting. DATROWAY was discovered by Daiichi Sankyo and is being jointly developed and commercialized with AstraZeneca. Final Phase 1b TROPION ...

AstraZeneca remains closely engaged with the government’s work to develop our new industrial strategy, and more broadly we continue to have a thriving life sciences sector, worth £108 billion ...

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ASCO 2025.

Thrombosis incidence in ANNEXA-I was 14.6% for andexanet vs. 6.9% for usual care. ANNEXA-I showed a 65.7% improvement in hemostasis for andexanet vs. 53% for usual care. The market’s back, and ...

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 4:15 pm ...

A meeting between AstraZeneca and the European Union to discuss COVID-19 vaccine supplies scheduled for Wednesday was postponed by the firm by a day, Austria's health minister said.

The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in ...